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Abstract
Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) and Trans-esophageal Ultrasound
Scanning with Fine Needle Aspiration (EUS-FNA) are important, novel techniques for the diagnosis and staging of non-small
cell lung cancer (NSCLC) that have been incorporated into lung cancer staging guidelines. To guide and optimize treatment
decisions, especially for NSCLC patients in stage III and IV, EGFR and KRAS mutation status is often required. The
concordance rate of the mutation analysis between these cytological aspirates and histological samples obtained by
surgical staging is unknown. Therefore, we studied the extent to which allele-specific quantitative real-time PCR with
hydrolysis probes could be reliably performed on EBUS and EUS fine needle aspirates by comparing the results with
histological material from the same patient. We analyzed a series of 43 NSCLC patients for whom cytological and
histological material was available. We demonstrated that these standard molecular techniques can be accurately applied
on fine needle cytological aspirates from NSCLC patients. Importantly, we show that all mutations detected in the
histological material of primary tumor were also identified in the cytological samples. We conclude that molecular profiling
can be reliably performed on fine needle cytology aspirates from NSCLC patients.
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Introduction
Lung cancer is the leading cause of cancer mortality in the
Western world [1]. For clinical and therapeutic purposes, lung
cancer is traditionally subdivided into small cell (SCLC) and non-
small cell lung cancer (NSCLC). Whereas SCLC is treated by
chemo- and/or radiotherapy, NSCLC is primarily treated through
resection; however, only 30% of NSCLC patients have a resectable
disease (stage I/II) at the time of presentation [2]. This underscores
the importance of accurate, preoperative mediastinal staging in
preventing unnecessary resections. Preoperative staging can be
performed through the transbronchial (EBUS-TBNA) or trans-
esophageal (EUS-FNA) aspiration of the mediastinal lymph nodes.
These cytological procedures are less invasive than routine
mediastinoscopy followed by biopsy of the lymph nodes, but similar
high specificity and sensitivity [3–9] are achieved. Endosonography
has been incorporated into lung cancer staging guidelines as an
alternative for the surgical staging of the mediastinum [10,11].
In many cases, the increased use of these minimally invasive
techniques is sufficient to diagnose and stage the patient correctly.
Although the amount of cellular material obtained by these
procedures is relatively small, the information requested by the
clinicians is rapidly growing, e.g., for NSCLC, immunohistochem-
istry and molecular pathology have become part of the standard
care [12].
In addition to this change in staging procedures, the rapid
development of new medical treatments for NSCLC patients has
taken place. A subset of NSCLC cancers may harbor an activating
mutation in the EGFR kinase domain [13]. Tumors with these
mutations are frequently sensitive to tyrosine kinase inhibitors
(TKIs). On the other hand, activating mutations in KRAS are
associated with resistance to TKIs. Although most publications
report that these mutations are mutually exclusive [14–19],
evidence suggests [20] that a tumor can simultaneously harbor an
activating EGFR mutation and mutations downstream in the
pathway in the KRAS gene, which means that upstream inhibition
of EGFR will have no therapeutic effect in these cases. Also,
mutations in BRAF and PIK3CA are reported in NSCLC. However,
further research is required to determine the extent to which these
mutations can have consequences for treatment [21,22].
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clinicians to minimize the delay of treatment, rapid and sensitive
molecular techniques are needed. Preferably, these techniques
should be applicable on formalin-fixed, paraffin-embedded (FFPE)
cytological samples [23–25] because EBUS-TBNA and EUS-FNA
aspiration samples are often the first material that is acquired from
patients with NSCLC. Allele-specific quantitative real-time PCR
(qPCR) with hydrolysis probes is a reliable and sensitive technique
that can be used for this purpose. Detecting mutations in EGFR,
KRAS, BRAF and PIK3CA with hydrolysis probes has been
previously described in NSCLC patients [23–26]. The sensitivity
of the assays also surpasses the 1% sensitivity proposal set for KRAS
mutation testing [27].
The majority of EGFR mutations are p.L858R, the hotspot
mutation in exon 21 and deletions in exon 19, which are reported
to comprise up to 36% of all activating mutations [15,28]. KRAS is
mutated in 10%–30% of lung carcinomas and over 95% of all
activating mutations in KRAS are located in exon 1 (codons 12 and
13) [28,29]. The BRAF p.V600E hotspot mutation is reported in
3% of NSCLC and alters residues important in AKT-mediated
BRAF phosphorylation, suggesting that the disruption of AKT-
induced BRAF inhibition plays a role in malignant transformation
[28,30]. Three hotspot mutations in PIK3CA may be another cause
of the over-activation of the PI3K–AKT pathway, which promotes
the malignant transformation of human airway epithelial cells and
has been reported in approximately 4% of lung carcinomas
[28,31].
In the current study, we compared allele-specific qPCR assays
for the most frequent activating mutations in EGFR, KRAS, BRAF
and PIK3CA in tumor-positive fine needle cytological aspirates
against histological material of primary tumors.
With this approach, we aimed to determine the extent to which
allele-specific qPCR with hydrolysis probes can be performed on
cytological aspiration material by comparing the mutation status
and then observing the concordance rate between the cytological
and histological material and between primary tumors and
metastases.
Materials and Methods
Ethics Statement
Specific need for ethics committee’s approval was not necessary
for this study. All samples were handled according to the medical
ethical guidelines described in the Code Proper Secondary Use of
Human Tissue established by the Dutch Federation of Medical
Sciences (www.federa.org, accessed October 27, 2010). Accord-
ingly to these guidelines all human material used in this study has
been anonymized since clinical data were not used. Because of this
anonymization procedure individual patients’ permission is not
needed.
Sample selection
Material from 43 patients with NSCLC for which both tumor-
positive cytological and histological material was available were
selected from the Department of Pathology in the Leiden
University Medical Center (LUMC) and identified through a
PALGA database search; non-gynecologic cytological samples
between 2005 and 2009 were searched using the search-strings
‘‘lung, malignant cells and non small cell lung cancer’’ and
‘‘mediastinum, malignant cells and non small cell lung cancer’’.
From the 447 unique cytological samples, we selected cases for
which tumor-positive histological material of the primary tumor
was also available (Supplementary Table S1). Of the 43 patients,
33 patients were subtyped: 14 squamous cell carcinomas, 15
adenocarcinomas, 3 adenosquamous carcinomas and 1 large cell
carcinoma. The remaining 10 patients had been classified NSCLC
only.
DNA from 42 control FFPE samples was obtained from the
Molecular Diagnostics (MD) section of the Department of
Pathology in the LUMC. For validation purposes, a series of 10
DNA samples, of which 9 had a demonstrated EGFR exon 19
deletion by DNA sequencing, was provided by the Netherlands
Cancer Institute - Antoni van Leeuwenhoek Hospital.
DNA isolation
Prior to DNA isolation, tumor cells were enriched to obtain
tumor cell percentages .70% (Figure 1). The FFPE tumor blocks
were enriched for tumor cells guided by a hematoxylin and eosin
(H&E)-stained slide taking 0.6-mm tissue punches from the tumor
focus in the FFPE block by using a tissue microarrayer (Beecher
Instruments, Sun Prairie, WI, USA). Prior to DNA isolation, the
tissue was deparaffinized in xylene and washed in 70% ethanol.
For the cell blocks, 10 slides of 10 mm were stained with
hematoxylin. Tumor cells were marked by guiding with a 5-mm
H&E slide and the corresponding tumor fields on the hematoxylin
slides were microdissected.
For the cytology smears, microdissection was initiated by
marking the tumor foci with a diamond needle on the back side
of the Giemsa-stained slide. Subsequently, cover slips were
removed by incubating in xylene at room temperature in separate
50-ml tubes to avoid contamination. Incubation was performed
overnight or until the cover slip was removed (sometimes up to a
week). Subsequently, the slides were washed in alcohol, three times
in 100%, once in 70% and once in 50%, to rehydrate the tissue.
Using a scalpel blade, the tumor foci from the marked areas were
scraped and collected in micro tubes for DNA isolation.
DNA was isolated using the NucleoSpin Tissue XS Genomic
DNA Purification kit (Machery-Nagel, Du ¨ren, Germany) accord-
ing to the manufacturer’s instructions. The average DNA yield
from the cytological smears and cell blocks was 282 ng and
280 ng, respectively. However, cytology smears were fixed using
Figure 1. Mediastinal lymph node cytology of a NSCLC patient.
Microscopical detail of a cytological smear obtained through fine
needle aspiration of a meadiastinal lymph node from a NSCLC patient.
The tumor foci are marked on the backside of each slide with a
diamond tip. Subsequently the coverslips are removed and tumor foci
are scraped from the slide using a scalpel blade (not shown).
doi:10.1371/journal.pone.0017791.g001
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to be of higher quality. The average DNA yield from the biopsies
was considerably higher (985 ng).
Prior to analysis, the DNA samples were diluted by 5 or 15
times. We observed that DNA diluted over 15 times generally gave
a quantification cycle (Cq).35 (data not shown); therefore, in the
subsequent assays, we used 56 stock DNA dilutions in sterile
water.
Mutation detection
The assays for the detection of seven different KRAS, three
PIK3CA and one BRAF variant were obtained through the Custom
TaqManH Assay Design Tool (Applied Biosystems, Nieuwerkerk
a/d IJssel, NL). Hydrolysis probes were designed with minor grove
binder (MGB) modifications at the 39-end. These modified probes
have the advantage that relatively short probes can be designed
with higher melting temperature (Tm) and increased duplex
stability and specificity in comparison to conventional probes [32].
The EGFR assays were described previously [33]. qPCR reactions
were performed in 10-ml reactions containing 5 ml of FastStart
Universal Probe Master (Roche Applied Science), 1 mlo f1 0 6
primer and hydrolysis probe solutions, 2 mlo f5 6 diluted DNA
and 2 ml of sterile water in a sealed LightCycler 480 Multiwell
Plate 384 (Roche Applied Science) in a LightCycler 480 system
(Roche Diagnostics) as follows: 10 minutes at 95uC and 45 cycles
of 15 seconds at 92uC, 60 seconds at 60uC and 10 seconds at
72uC. For validation, we performed direct Sanger sequencing
using M13 primers as described previously [34] at the sequencing
core of the Leiden Genome Technology Center. Primer sequences
are listed in Supplementary Table S2. All DNA Sequencing was
completed on known genes and no new sequencing was
completed.
Raw data from the LC480 software were imported into an in-
house–created Microsoft Excel 2003 spreadsheet to define the
mutation status. The quantification cycle (Cq) was used for quality
assessment and samples with Cq values exceeding 35 (Cq.35) in
the wild-type channel were rejected and excluded for further
analysis. To determine the presence or absence of a mutation, the
endpoint fluorescence ratio Rm/Rwt was calculated after subtract-
ing the average background signal from three negative controls.
The spreadsheet is available upon request. For BRAF, PIK3CA and
EGFR p.L858R, mutation status was directly discriminated
(Figure 2a). Mutations were identified when the Rm/Rwt ratio
was higher than 0.7, while a ratio lower than 0.3 indicated the
absence of a mutation. No intermediate values were observed. In
KRAS wild-type samples, an increased background signal was
observed for the c.34G.T( R m/Rwt60.4) and c.38G.C( R m/
Rwt60.6) assay in the mutant probe channel. This was probably
caused by imperfect hybridization of these probes to the wild-type
allele. The setting to identify the mutation correctly was c.34G.T
Rm/Rwt.0.7, while the c.38G.T mutant was identified when an
Rm/Rwt ratio cut-off of 0.8 was used. The EGFR exon 19 deletion
probe resulted in a drop in endpoint fluorescence, while in a wild-
type sample, both probes gave a signal. To analyze EGFR exon 19
deletions, Rm/Rwt.0.8 and Cq,32 were considered wild-type
and Rm/Rwt#0.6 and Cq,32 indicated a deletion. Intermediate
values, with Rm/Rwt ratio between 0.6 and 0.8 and Cq,35,
required confirmation using Sanger sequencing.
Results and Discussion
Assay design and validation
For BRAF, a single assay was designed that detects the activating
hotspot mutation p.V600E, which results from the c.1799T.A
substitution [35]. For PIK3CA, we designed probes for the three
most common substitutions [36]: c.1624G.A (p.E542K),
c.1633G.A (p.E545K) and c.3140A.G (p.H1047R). Although
these three assays detected over 85% of all mutations in NSCLC,
Figure 2. qPCR Results for the EGFR assays. Panel A shows the EGFR p.L858R assay. All samples show a wild type (control) signal, VIC, lower
panel (green and blue lines) while only group 2 (blue line) shows a mutant FAM signal. Panel B shows the EGFR exon 19 mutation assay. The lower
panel shows the wildtype VIC signal for all samples (red, green and purple lines). The top panels shows the mutant FAM signal. Group 1 (red lines)
shows the wildtype signal, Group 2 (red and purple) shows possible mutants with decreased fluorescence, group 3 (green line) show an almost
completely disappeared signal indicating a deletion. The images are obtained from the LC480 software release 1.5.0. The y-axis shows the relative
fluorescence for the FAM (465–510 nm) and VIC (533–580nm) probes, x-axis shows the PCR cycles.
doi:10.1371/journal.pone.0017791.g002
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potentially missed. For KRAS, we designed assays for the seven
most frequent base pair substitutions in codons 12 and 13:
c.34G.A (p.G12S), c.34G.C, (p.G12R), c.34G.T, (p.G12C),
c.35G.A, (p.G12D), c.35G.C, (p.G12A), c.35G.T (p.G12V)
and c.38G.A (p.G13D). Together, these assays detect almost all
substitutions in KRAS, although some rare variants might be
missed. To detect the p.L858R hotspot and exon 19 deletions in
EGFR we used previously reported assays [33]. The EGFR
p.L858R mutation was detected using a probe mix containing a
wild-type probe and two different mutant probes: one for the most
common variant (c.2573T.G) and one for the rare complex
c.2573_2574TG.GT inversion.
Hotspot mutation analysis in cytology material from
NSCLC patients
To address the extent to which the mutation analysis can be
reliably performed on EBUS-TBNA and EUS-FNA aspiration
material, we performed the 13 assays on 43 patients with NSCLC
for which both primary tumor (either biopsies or histological
material from resections) and tumor-positive cytological material
had been collected. The material from the 43 patients represents
29 tissue cores from histological excisions, 23 microdissected
biopsies and 3 whole-section biopsies which were compared to 45
microdissected cytological smears and 17 microdissected cell
blocks (Supplementary Table S1).
Six patients presented with a KRAS mutation: c.34G.T (N=2),
c.34G.A, c.35G.A, c.35G.C and c.38G.A. One patient
carried a deletion in exon 19 of EGFR (c.2238_2252del15) and two
patients showed PIK3CA mutations: c.1633G.A and c.3140A.G.
The latter case showed an additional KRAS mutation (p.34G.T).
No mutations in BRAF were observed.
For some patients, multiple histological and/or cytological
samples were analyzed. In different samples for the same patient,
conflicting results for the same type of material were never
observed. Therefore in table 1 each patient is represented only
once, where for each type of material the information from all the
patient’s samples is merged. This means that the clearest signal for
each assay took precedence. In table 1, the remaining missing
calls, due to low signals are indicated by ‘‘?’’.
The overall call rate in the 13 assays, after merging, amounts to
95% (58 undetermined results out of 1118 tests). The call rate for
histological material is substantially higher at 99% (8 undeter-
mined out of 559) than for cytological material at 91% (48 out of
559). Within the cytological material, the call rate for primary
tumors is lower (84%) than for metastases (96%). Note that these
observations remain if the patient with the lowest quality results
(sample 21) is removed. Within the histological material the same
difference in call rate can be observed, but in a much lower degree
(98% for primary tumors versus 99% for metastases). When
comparing call rates per assay, we observed that the three assays
on the PIK3CA gene performed less (between 88 and 91%) than
the other 10 assays (between 94 and 99%).
As could be observed, when cytological material was obtained
from primary tumors, the mutation results for histology and
cytology were concordant in all cases where both results were
determined. When cytological material was obtained from
metastasis, in one patient (nr 40) with an adenocarcinoma/
bronchoalveolar cell carcinoma (BAC), a KRAS c.34G.A
mutation was identified in the mediastinal lymph node which
was not detected in the primary tumor. This could be explained by
the commonly observed genetic divergence of metastasis from its
primary tumor. In this case the time-span is 18 years between the
primary tumor and the metastasis. Overall, the discordance rate is
only 0.20% (1 assay out of 503 where both histological and
cytological results are determined).
Tumor cell percentage and DNA quality
From biopsies and cytology, only small tumor foci can be
microdissected. This results in a low DNA yield that, in case of
formalin fixation, is also partially degraded. To study the quality of
the DNA, we compared the DNA yield to assay performance. We
observed that the average amount of DNA isolated (295 ng) was
lower in the group (n=15) where two or more assays failed [as
compared to the group without failing assays (n=102, 2973 ng)].
Nevertheless, in the latter group, 44% of the samples (n=45) also
had a DNA amount of lower than 295 ng. This indicates that Cq
values are a better indicator of DNA quality and performance than
DNA concentration measurements.
Allele-specific qPCR with hydrolysis probes has been reported
to surpass the 1% sensitivity level [27]. However, considering that
the qPCR efficiency also depends on DNA fragmentation, the
DNA isolated from FFPE samples could accurately be analyzed at
a sensitivity level of 10% [26]. We determined the detection limit
in serial dilutions of DNA from two tumors carrying a KRAS
c.34G.T or a c.35G.A mutation. This showed that the minimal
DNA input must be at least 32 pg, the equivalent of 4–6 cells of
high molecular DNA, to give Cq values ,35 (Figure 3).
Furthermore, we validated the assays in a series of DNA isolates
from microdissected FFPE samples with known KRAS, PIK3CA,
BRAF or EFGR variants as determined by Sanger sequencing. We
found a 100% correlation with the hydrolysis probe assays.
We validated the assay for EGFR exon 19 in a series of 10
samples with possible sequence verified exon 19 deletions and a
tumor percentage of more than 50%. The samples were tested
without prior knowledge of the mutation status. The hydrolysis
assay results were compared with the DNA sequence results and
all nine samples containing an exon 19 deletion were correctly
identified and distinguished from the wild-type specimen
(Figure 2b). In one case, there was an 18-bp insertion in exon
19. Because this fell outside the detection area of the probes, the
mutant was not detected by the deletion assay (SampleID 1012 in
Supplementary Table S3). These results show that all hotspot
mutations and EGFR exon 19 deletions can be detected using the
hydrolysis probes.
Cross-reactivity
Mutations in KRAS and PIK3CA cluster in hotspots. For KRAS,
all seven assays hybridized to codons 12 and 13 (nucleotides
c.34G, c.35G and c.38G), while for PIK3CA two assays detected
exon 9 changes (c.1624G.A and c.1633G.A). As the probes
potentially hybridized in the same region, cross-reactivity between
the different KRAS or PIK3CA assays might be observed as a result
of increased fluorescence readings from imperfectly matched
probes or primers [26]. Additionally, cross-reactivity might result
from (rare) base pair substitutions that are not covered by the used
assays.
Cross-reactivity was studied in a series of 42 MD samples
carrying a KRAS mutation at position 34, 35 or 38. A total of 294
assays (4267) were performed. The correct mutation status was
identified when an Rm/Rwt ratio cut-off .0.7 was used; however,
in 68 assays, a cross-reactivity signal was observed. Five cross-
reactivity signals had Rm/Rwt.0.7, but in these cases, the assay
for the genuine mutation had Rm/Rwt.1.0. Cross-reactivity was
only observed for probes covering the same base pair position (at
position 34 or 35). Cross-reactivity between signals from base pair
34 or 35 and position 38 was not observed (Supplementary Table
NSCLC Mutation Analysis after Fine Needle Cytology
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observed for the two different PIK3CA probes.
Clinical practice
The described methods can be implemented in clinical practice.
The molecular diagnostics test results can be generated in a short
time. In daily practice, the cytological EBUS-TBNA or EUS-FNA
aspiration material is morphologically typed by pathologists.
Subsequently, samples are clustered for microdissection on a
weekly basis. Microdissection is essential to obtain high tumor cell
percentages to detect the EGFR exon 19 deletion, and to allow
other analyses with lower sensitivity than the described method,
e.g Sanger sequencing. After DNA isolation, the hydrolysis probe
assays are performed on the DNA dilutions. At the end of the
second day, the qPCR results are analyzed in an in-house–
developed Microsoft Excel–based analysis tool to interpret the
results, e.g., determine the mutation status of each probe and
interpret the effect of cross-reactivity. The results are subsequently
reported to the clinic. A limitation of hotspot analysis is, by
definition, that only the hotspot mutations are detected, while
Sanger sequencing can identify all mutations in the PCR
amplicon. In some cases, in which the mutation analysis does
not meet the quality settings, Sanger sequencing will be
performed. For Sanger sequencing, extra PCR reactions, reaction
product purifications and electrophoresis must be performed,
which will require two extra days in the analysis pipeline.
Conclusion
We conclude that somatic mutation hotspot analysis for KRAS,
PIK3CA, BRAF and EGFR of fine needle aspirations of mediastinal
Figure 3. Effect of the DNA concentration on the c.34G.T KRAS assay. The top panel shows the mutant (FAM) signal for a range of different
amounts of input DNA in pg carrying the c.34G.T KRAS mutation. No ‘‘mutant’’ signal is observed in a wildtype DNA (green line) and water control
(grey line). In the wildtype (VIC) panel all DNA’s show a wildtype signal while the water control is negative (grey line). The images are obtained from
the LC480 software release 1.5.0. The y-axis shows the relative fluorescence for the FAM (465–510 nm) and VIC (533–580nm) probes, x-axis shows the
PCR cycles.
doi:10.1371/journal.pone.0017791.g003
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PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17791lymph nodes in NSCLC patients is accurate and reliable. Somatic
hotspot mutation analysis for KRAS, PIK3CA, BRAF and EGFR can
reliably be performed using allele-specific qPCR with hydrolysis
probes; the mutation results from cytological specimens and the
primary tumors are highly concordant.
Somatic mutation analysis in NSCLC for molecular staging and
the guidance of treatment decisions can be performed on EBUS
and EUS fine needle aspirates, procedures that are less invasive for
the patient than routine mediastinoscopy.
Our findings indicate that the molecular genetic analysis of
NSCLC should be incorporated with the standard EBUS and EUS
procedures. This combined approach will result in the accurate
diagnosing and staging of those patients and will alsohelpto guide the
optimal treatment decisions, especially in stage III and IV NSCLC.
Supporting Information
Table S1 General overview.
(XLS)
Table S2 Primer sequences.
(XLS)
Table S3 EGFR exon 19 validation experiment.
(XLS)
Table S4 Cross reactivity in KRAS assays.
(XLS)
Acknowledgments
We thank the technicians at the Molecular Diagnostics group in the
LUMC Department of Pathology for testing the protocols in different
biological settings and troubleshooting the various aspects of the study.
Author Contributions
Conceived and designed the experiments: RvE JL MS MTY JTA HM
TvW. Performed the experiments: RvE JL MS. Analyzed the data: RvE JL
DR MS HM PMN VS TvW. Contributed reagents/materials/analysis
tools: RvE MTY PMN JTA. Wrote the paper: RvE JL MTY GIF PMN
JTA VS HM TvW. Performed pathology: JL MV VS HM. Contributed
clinical background: MTY KFR JTA. Performed molecular diagnostics:
GIF PMN TvW.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global Cancer Statistics, 2002. CA
Cancer J Clin 55: 74–108.
2. Molina JR, Adjei AA, Jett JR (2006) Advances in Chemotherapy of Non-small
Cell Lung Cancer*. Chest 130: 1211–1219.
3. Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, et al. (2009) Endobronchial
ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a
systematic review and meta-analysis. Eur J Cancer 45: 1389–1396.
4. Annema JT, Versteegh MI, Veselic M, Welker L, Mauad T, et al. (2005)
Endoscopic Ultrasound Added to Mediastinoscopy for Preoperative Staging of
Patients With Lung Cancer. JAMA 294: 931–936.
5. Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, et al. (2007) Detection of
Epidermal Growth Factor Receptor Mutation in Transbronchial Needle
Aspirates of Non-Small Cell Lung Cancer*. Chest 131: 1628–1634.
6. Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Kubo R, et al. (2007)
Assessment of Epidermal Growth Factor Receptor Mutation by Endobronchial
Ultrasound-Guided Transbronchial Needle Aspiration*. Chest 132: 597–602.
7. Tournoy KG, Rintoul RC, van Meerbeeck JP, Carroll NR, Praet M, et al.
(2009) EBUS-TBNA for the diagnosis of central parenchymal lung lesions not
visible at routine bronchoscopy. Lung Cancer 63: 45–49.
8. Micames CG, McCrory DC, Pavey DA, Jowell PS, Gress FG (2007) Endoscopic
ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging:
A systematic review and metaanalysis. Chest 131: 539–548.
9. Annema JT, Versteegh MI, Veselic M, Voigt P, Rabe KF (2005) Endoscopic
ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung
cancer and its impact on surgical staging. J Clin Oncol 23: 8357–8361.
10. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA (2007)
Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical
practice guidelines (2nd edition). Chest 132: 202S–220S.
11. De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, et al. (2007)
ESTS guidelines for preoperative lymph node staging for non-small cell lung
cancer. Eur J Cardiothorac Surg 32: 1–8.
12. Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M (2009) Review Article:
A Reevaluation of the Clinical Significance of Histological Subtyping of Non–
Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized
Treatments. International Journal of Surgical Pathology 17: 206–218.
13. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-
cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Oncogene 28 Suppl 1: S24–S31.
14. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH (2009) EGFR and KRAS
mutations in patients with adenocarcinoma of the lung. Korean J Intern Med 24:
48–54.
15. Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted
therapy and beyond. Mod Pathol 21 Suppl 2: S16–S22.
16. Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, et al. (2009) Using whole
genome amplification (WGA) of low-volume biopsies to assess the prognostic
role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small
cell lung cancer (NSCLC). J Thorac Oncol 4: 12–21.
17. Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, et al. (2010) A
comparison of EGFR and KRAS status in primary lung carcinoma and matched
metastases. Human Pathology 41: 94–102.
18. Motoi N, Szoke J, Riely GJ, Seshan VE, Kris MG, et al. (2008) Lung
Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the
Major Histologic Subtype Suggests Correlations Between Papillary and
Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene
Expression Analysis. The American Journal of Surgical Pathology 32.
19. Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, et al. (2007) Nras and Kras
mutation in Japanese lung cancer patients: Genotyping analysis using Light-
Cycler. Oncol Rep 18: 623–628.
20. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, et al.
(2008) Comparison of EGFR and K-RAS gene status between primary tumours
and corresponding metastases in NSCLC. Br J Cancer 99: 923–929.
21. Hirsch FR, Varella-Garcia M, Bunn PA Jr., Franklin WA, Dziadziuszko R,
et al. (2006) Molecular Predictors of Outcome With Gefitinib in a Phase III
Placebo-Controlled Study in Advanced Non-Small-Cell Lung Cancer. J Clin
Oncol 24: 5034–5042.
22. Zou ZQ, Zhang XH, Wang F, Shen QJ, Xu J, et al. (2009) A novel dual
PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small
cell lung cancer cells. Int J Mol Med 24: 97–101.
23. Boldrini L, Gisfredi S, Ursino S, Camacci T, Baldini E, et al. (2007) Mutational
Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A
Sensitive Method for Molecular Diagnosis. Journal of Thoracic Oncology 2.
24. Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, et al. (2005) Epidermal
growth factor receptor gene mutation in non-small cell lung cancer using highly
sensitive and fast TaqMan PCR assay. Lung Cancer 50: 375–384.
25. Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, CastellA ˜ E, et al.
(2008) A Sensitive Method for Detecting EGFR Mutations in Non-small Cell
Lung Cancer Samples with Few Tumor Cells. Journal of Thoracic Oncology 3.
26. Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, et al. (2009)
Targeted KRAS mutation assessment on patient tumor histologic material in
real time diagnostics. PLoS One 4: e7746.
27. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, et al. (2008) KRAS
mutation testing for predicting response to anti-EGFR therapy for colorectal
carcinoma: proposal for an European quality assurance program. Virchows
Arch 453: 417–431.
28. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The
Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum
Genet Chapter 10: Unit.
29. Jancik S, Drabek J, Radzioch D, Hajduch M (2010) Clinical relevance of KRAS
in human cancers. J Biomed Biotechnol 2010: 150960.
30. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, et al. (2002) BRAF and
RAS Mutations in Human Lung Cancer and Melanoma. Cancer Research 62:
6997–7000.
31. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, et al. (2007) PIK3CA
mutation and amplification in human lung cancer. Pathol Int 57: 664–
671.
32. Kutyavin IV, Afonina IA, Mills A, Gorn VV, Lukhtanov EA, et al. (2000) 39-
minor groove binder-DNA probes increase sequence specificity at PCR
extension temperatures. Nucleic Acids Res 28: 655–661.
33. Yung TK, Chan KC, Mok TS, Tong J, To KF, et al. (2009) Single-molecule
detection of epidermal growth factor receptor mutations in plasma by
microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer
Res 15: 2076–2084.
34. van Eijk R, van Puijenbroek M, Chhatta AR, Gupta N, Vossen RH, et al. (2010)
Sensitive and specific KRAS somatic mutation analysis on whole-genome
amplified DNA from archival tissues. J Mol Diagn 12: 27–34.
NSCLC Mutation Analysis after Fine Needle Cytology
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e1779135. Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, et al. (2006) Detection of
BRAF V600E mutation in colorectal cancer: comparison of automatic
sequencing and real-time chemistry methodology. J Mol Diagn 8: 540–543.
36. Samuels Y, Velculescu VE (2004) Oncogenic mutations of PIK3CA in human
cancers. Cell Cycle 3: 1221–1224.
NSCLC Mutation Analysis after Fine Needle Cytology
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17791